Tarceva Advisory Committee To Focus On Treatment Alternatives, Subgroup Concerns
This article was originally published in The Pink Sheet Daily
Executive Summary
ODAC will review currently available treatment options and negative treatment effects in subgroups as OSI seeks to expand Tarceva's indication to first-line maintenance and monotherapy in NSCLC.
You may also be interested in...
Will Maintenance Sell In NSCLC? Experts Weigh Costs Against Benefits
Longer-term "maintenance" therapy may be the new frontier for oncology products as cancer evolves into a chronic, manageable disease – a shift that will provide benefits for patients and the pharmaceutical industry. But as cancer drug costs continue to skyrocket and cost-effectiveness discussions become more commonplace, that transition may not come as smoothly as industry would like.
Will Maintenance Sell In NSCLC? Experts Weigh Costs Against Benefits
Longer-term "maintenance" therapy may be the new frontier for oncology products as cancer evolves into a chronic, manageable disease – a shift that will provide benefits for patients and the pharmaceutical industry. But as cancer drug costs continue to skyrocket and cost-effectiveness discussions become more commonplace, that transition may not come as smoothly as industry would like.
Tarceva Gets Thumbs Down For NSCLC: Cmte. Seeks Better Subgroup Analysis
The Oncologic Drugs Advisory Committee's rejection of OSI Pharmaceutical's Tarceva as maintenance therapy for non-small cell lung cancer seems an example of the increasingly specialized and intense nature of drug development: the panel wanted bigger, larger studies with more subgroup analyses